Psyence Biomedical (PBM) Net Cash Flow (2023)

Psyence Biomedical (PBM) recorded quarterly Net Cash Flow of -$1.6 million in Q1 2023.

Psyence Biomedical (PBM) Net Cash Flow (2023) Analysis & Trends

Psyence Biomedical's Net Cash Flow history runs 1 years deep, the most recent figure standing at -$1.6 million for Q1 2023.

In Q1 2023, Net Cash Flow changed N/A year-over-year to -$1.6 million; the TTM figure through Mar 2025 stood at -$1.6 million (changed N/A YoY), while the FY2024 annual figure was -$3.0 million, down 604.05% from the prior year.
Net Cash Flow was -$1.6 million for Q1 2023 at Psyence Biomedical.
In the past five years, Net Cash Flow ranged from a high of -$1.6 million in Q1 2023 to a low of -$1.6 million in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	2.44 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	625.70 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-2.44 Mn
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	457.40 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	664,983.53
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn	-152.20 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2023	-1.59 Mn
Mar 31, 2023	-1.59 Mn